Chevaliez Stéphane, Pawlotsky Jean-Michel
French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hôpital Henri Mondor, Université Paris 12, Créteil, France.
Adv Drug Deliv Rev. 2007 Oct 10;59(12):1222-41. doi: 10.1016/j.addr.2007.07.002. Epub 2007 Aug 11.
In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN). The first clinical trial of recombinant IFN-alpha in patients with chronic hepatitis C was published in 1986. This article reviews the classification of IFNs, IFN production during viral infections, IFN signaling pathways and the mechanisms of their antiviral and immunomodulatory properties. Hepatitis C virus infection treatment is currently based on the combination of pegylated IFN-alpha and ribavirin. The pegylated IFN-alpha molecules are described, as well as the putative mechanisms of action of ribavirin. Current treatment guidelines are discussed and new results suggesting that the treatment schedule should be tailored to the early virological response during therapy are presented. Finally, insights into new hepatitis C drug developments are given.
2007年，全世界庆祝了干扰素（IFN）发现50周年。1986年发表了重组α干扰素用于慢性丙型肝炎患者的首例临床试验。本文综述了干扰素的分类、病毒感染期间干扰素的产生、干扰素信号通路及其抗病毒和免疫调节特性的机制。目前丙型肝炎病毒感染的治疗基于聚乙二醇化α干扰素和利巴韦林的联合使用。文中描述了聚乙二醇化α干扰素分子以及利巴韦林的假定作用机制。讨论了当前的治疗指南，并介绍了新的研究结果，这些结果表明治疗方案应根据治疗期间的早期病毒学应答进行调整。最后，对丙型肝炎新药研发的见解也作了阐述。
